DB17563InvestigationalProtein Based Therapies
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate...
- Mechanism
- Curator reviewed
Pharmacologically active on Folate receptor alpha and Tubulin
- Code names
- STRO-002
Resolves to
Compound
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with Luveltamab tazevibulin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account